Rituxan (rituximab) / Zenyaku Holdings, Biogen, Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

545 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rituxan (rituximab) / Roche
NCT05877040 / 2018-001347-31: A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy

Active, not recruiting
2
20
Europe
Rituximab
Istituto Clinico Humanitas, Ministero della Salute
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
03/23
09/23
NCT01811368: Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
20
US
rituximab, IDEC-C2B8, Mabthera, Rituxan, ibritumomab tiuxetan, Zevalin, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, total nodal irradiation, TLI, total lymphoid irradiation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, allogeneic hematopoietic stem cell transplantation, cyclosporine, cyclosporin, cyclosporin A, CYSP, Sandimmune, mycophenolate mofetil, Cellcept, MMF
Joseph Tuscano, Spectrum Pharmaceuticals, Inc
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
04/23
12/23
COMBIVAS, NCT03967925 / 2017-004645-24: Rituximab and Belimumab Combination Therapy in PR3 Vasculitis

Active, not recruiting
2
31
Europe
Belimumab, Benlysta, Rituximab, Truxima, Prednisolone, prednisone
Rachel Jones, GlaxoSmithKline, Medical Research Council, Imperial College London, University College, London, Newcastle University, University of Glasgow, University of Cambridge
ANCA Associated Vasculitis, Granulomatosis With Polyangiitis
04/23
11/23
NCT04899570: Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Recruiting
2
20
RoW
Zanubrutinib, BRUKINSA, Rituximab, Rituxan, Cyclophosphamide, Epirubicin, Vindesine, Prednisone
Peking Union Medical College Hospital
Intravascular Large B-Cell Lymphoma
04/23
04/25
NCT04375228: Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Recruiting
2
30
US
Rituximab, RITUXAN, Tocilizumab, ACTEMRA
Columbia University, Genentech, Inc.
Immune-related Adverse Events, Advanced Solid Tumor
05/24
05/25
NCT05425654: RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

Recruiting
2
30
RoW
Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide, Busulfan, Carmustine, and Cyclophosphamide
National Research Center for Hematology, Russia
Primary CNS Lymphoma
05/23
05/26
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
RMO, NCT05549284: Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)

Recruiting
2
36
RoW
Orelabrutinib,Rituximab and Methotrexate, RMO
Affiliated Hospital to Academy of Military Medical Sciences
Primary Central Nervous System Lymphoma
05/23
05/26
ChiCTR2200061041: Prospective, multicenter, single-arm, open phase II clinical study of orelabrutinib in combination with lenalidomide and rituximab in patients with newly treated mantle cell lymphoma

Not yet recruiting
2
5
 
OLR
Tianjin Tumor Hospital; Tianjin Tumor Hospital, Provided by the sponsor
Untreated mantle cell lymphoma
 
 
CREDIT, NCT05093140: Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL

Not yet recruiting
2
30
NA
Camrelizumab, Rituximab, Cyclophosphamide, Hydroxyldaunorubicin, Vincristine, Prednisone
Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd.
Primary Extranodal Lymphoma, DLBCL
06/23
12/24
2019-004540-29: The effectivness and safety of ponatinib administered in combination with reduced chemotherapy in treatment of acute lymphoblastic leukemia in adults. Účinnost a bezpečnost ponatinibu podaného v kombinaci s redukovanou chemoterapií v léčbě akutní lymfoblastové leukémie dospělých

Not yet recruiting
2
32
RoW
cytarabine, cyclophosphamide, Dexamethasone, rituximab, vincristine, methotrexate, filgrastim, Film-coated tablet, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Injection, ICLUSIG 15 mg film-coated tablets
Ústav hematologie a krevní transfuze, Incyte Biosciences Distribution B.V., CZECRIN - Czech Clinical Research Infrastructure Network
NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA NOVĚ DIAGNOSTIKOVANÁ AKUTNÍ LYMFOBLASTOVÁ LEUKÉMIE S POZITIVITOU FILADELFSKÉHO CHROMOSOMU, Untreated Ph+ Acute Lymphoblastic Leukemia Neléčená Ph+ akutní lymfoblastová leukémie, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
PALG ALL7, NCT04920968: Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/ OVERALL

Not yet recruiting
2
124
Europe
Obinutuzumab, Rituximab, Activ comparator
Maria Sklodowska-Curie Institute - Oncology Center, KCRI
CD20-positive Acute Lymphoblastic Leukemia
06/23
12/24
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Recruiting
2
90
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
06/24
07/27
NCT04004819: Rituximab for HTLV-1-associated Myelopathy

Recruiting
2
100
RoW
Rituximab
First Affiliated Hospital of Fujian Medical University
HTLV-1-associated Myelopathy
07/23
07/24
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
08/24
08/24
ChiCTR2100049862: A multicenter, phase II, prospective study of orelabrutinib combined with rituximab and methotrexate regimen in untreated primary central nervous system lymphoma

Not yet recruiting
2
36
 
Orelabrutinib+Rituximab+Methotrexate
Department of lymphoma and plasmacytoma disease, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital; Department of lymphoma and plasmacytoma disease, Senior Department of Hematology，the Fifth Medical Center of PLA General Hospital, None
primary central nervous system lymphoma
 
 
NCT06468943: Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Enrolling by invitation
2
20
RoW
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
The First Affiliated Hospital of Soochow University
Effects of Chemotherapy, Safety Issues
05/26
05/28
NCT04021992: GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

Recruiting
2
48
RoW
gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab
Sun Yat-sen University
Lymphoma, Large B-Cell, Diffuse
07/23
12/23
Jinzm 004, NCT05504603: Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

Recruiting
2
20
RoW
zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance
The First Affiliated Hospital of Soochow University
Untreated Mantle Cell Lymphoma
07/23
07/25
NCT04989621: Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Recruiting
2
32
RoW
Orelabrutinib and Rituximab, induction treatment, Orelabrutinib
Sun Yat-sen University
Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma
08/23
08/23
NCT01810588: Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Active, not recruiting
2
273
US
CliniMACS® CD34 Reagent System, Fludarabine, Fludara, Fludarabine phosphate, Melphalan, anti-thymocyte globulin (rabbit), rATG, Rabbit ATG, Rituximab, Rituxan, Total Body Irradiation, TBI, Mycophenolate Mofetil, Cellcept, MMF, Tacrolimus, Prograf
Weill Medical College of Cornell University
Hematologic Malignancies
08/23
04/28
NCT02532257: Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Completed
2
46
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Janssen, LP
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, CD20 Positive, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
08/23
08/23
NCT03995147: Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Recruiting
2
51
US
Pembrolizumab, R-CHOP Protocol, Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone
University of Chicago, Merck Sharp & Dohme LLC
B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
08/24
08/24
NCT03837873: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Recruiting
2
118
RoW
Rituximab, Etoposide, Vincristine, Doxorubicin, Dexamethasone, Cyclophosphamide, Lenalidomide, Cisplatin, Cytarabine
Institute of Hematology & Blood Diseases Hospital
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
09/23
09/24
NCT03736616: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Recruiting
2
47
US
Carboplatin, Ifosfamide, Etoposide, VP-16, Rituximab, Rituxan, Carmustine, BCNU, Cytarabine, ARA-C, Melphalan, Autologous HSCT, Autologous Hematopoeitic Stem Cell Transplantation, Acalabrutinib
Swedish Medical Center, Acerta Pharma BV
Diffuse Large B Cell Lymphoma
09/23
09/23
NCT03804359: Personalized Medicine for Membranous Nephropathy

Recruiting
2
64
Europe
Rituximab
Centre Hospitalier Universitaire de Nice
Idiopathic Membranous Nephropathy
09/23
09/23
NCI-2022-02150, NCT05293509: Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Withdrawn
2
24
US
Fludarabine, Fludara™, Dexamethasone, Cyclophosphamide, Cytoxan™, Bortezomib, Velcade®, Rituximab, Rituxan®, Busulfan, Busulfex™, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG
M.D. Anderson Cancer Center
Stem Cell Transplantation
09/23
09/23
NCT04214626: R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Active, not recruiting
2
60
RoW
Rituximab, RiTUXimab Injection, Lenalidomide, Lenalidomide capsule, Cyclophosphamide, Cyclophosphamide Injection, Epirubicin, Epirubicin hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product, Methotrexate, Methotrexate Injectable Solution
Henan Cancer Hospital
Diffuse Large B Cell Lymphoma
11/23
01/25
NCT04566887: Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

Active, not recruiting
2
54
Canada
Acalabrutinib, R-CHOP chemotherapy
University Health Network, Toronto
Mantle Cell Lymphoma
09/23
11/28
NCT06176729: Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Recruiting
2
30
RoW
Polatuzumab Vedotin, Rituximab, Lenalidomide
Yan Zhang, MD, Peking University Third Hospital, Peking University First Hospital, Chinese PLA General Hospital
Diffuse Large B Cell Lymphoma
10/25
10/27
SINAPPS2, NCT03194815: IVIG and Rituximab in Antibody-associated Psychosis -

Recruiting
2
70
Europe
Intravenous immunoglobulin, IVIG, Intratect, Placebo, Saline solution, Rituximab, MabThera
University of Cambridge, University of Oxford
Psychosis, Autoimmune Encephalitis
03/26
03/26
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Recruiting
2
208
Europe, RoW
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
NCT02633137: Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Completed
2
49
US
Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC)
Memorial Sloan Kettering Cancer Center, Celgene Corporation
Mantle Cell Lymphoma, Untreated
11/23
11/23
NCT04479267: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Recruiting
2
49
US
Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione, 53-03-2, Adasone, Cortancyl, Dacortin, , Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, 1,2-Dehydrohydrocortisone, 50-24-8, 9120, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Methylprednisolone, (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione, 6Alpha-Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Rituximab, 174722-31-7, 687451, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, POLATUZUMAB VEDOTIN, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Cyclophosphamide, 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Doxorubicin Hydrochloride, 14-Hydroxydaunorubicin Hydrochloride, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma
11/25
11/26
NCT06136351: A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Recruiting
2
23
RoW
Zanubrutinib, Rituximab, Bendamustin
Ruijin Hospital
Lymphoma, Mantle-Cell
11/27
11/27
NCT06158399: AZA Combined With RCHOP in P53-mutated DLBCL.

Recruiting
2
52
RoW
Azacitidine in combination with R-CHOP
The First Affiliated Hospital of Xiamen University, Jiangsu Provincial People's Hospital, Sun Yat-sen University, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital
DLBCL - Diffuse Large B Cell Lymphoma, TP53
05/25
05/25
RIFIREINS, NCT03970577 / 2018-003437-15: RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome

Recruiting
2
148
Europe
Rituximab, Mabthéra, Prednisone, Cortancyl
Assistance Publique - Hôpitaux de Paris
Minimal Change Nephrotic Syndrome (MCNS)
11/23
11/23
NCT03919175: Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Terminated
2
18
US
Umbralisib, TGR-1202, Rituximab, MabThera
Massachusetts General Hospital, TG Therapeutics
Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma Grade 2, Follicular Lymphoma Grade IIIa, Marginal Zone Lymphoma, Marginal Zone B Cell Lymphoma
05/24
05/24
BIOVAS, NCT05168475 / 2019-003964-30: Biologics in Refractory Vasculitis

Active, not recruiting
2
18
Europe
Rituximab, Infliximab, Tocilizumab
Cambridge University Hospitals NHS Foundation Trust
Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis, Cryoglobulinemic Vasculitis, IgA Vasculitis, Polyarteritis Nodosa, Cutaneous Polyarteritis Nodosa, Primary Angiitis of Central Nervous System
11/23
06/24
NCT03688451: Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma

Active, not recruiting
2
20
US
Rituximab
Tahir Latif
Non Hodgkin Lymphoma
12/23
10/24
NCT03609593: Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Active, not recruiting
2
42
US
Bendamustine, Treanda, Venetoclax, ABT-199, Venclexta, Rituximab, Rituxan
Nicole Lamanna
Chronic Lymphocytic Leukemia
01/25
12/25
NCT05586737: Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency

Recruiting
2
15
Europe
Rituximab
Angelica Lindén Hirschberg
Autoimmune Diseases, Premature Ovarian Insufficiency
12/23
12/24
NCT04433156: VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Recruiting
2
60
RoW
Bortezomib, Bortezomib Injection, Rituximab, RiTUXimab Injection, Epirubicin, Epirubicin hydrochloride, Cyclophosphamide, Cyclophosphamide Injection, Prednisone, Prednisone Oral Product
Henan Cancer Hospital
Marginal Zone Lymphoma
12/23
04/25
ChiCTR2100053805: Prospective, multicenter phase II clinical study of orelabrutinib combined with immunochemotherapy in the treatment of newly treated high-risk diffuse large B-cell lymphoma

Recruiting
2
100
 
Orelabrutinib + RCHOP ;Orelabrutinib + R-DA-EPOCH ;Orelabrutinib + R-HD-MTX
The Third People's Hospital of Fujian Province; The Third People's Hospital of Fujian Province, Beijing Innocare Pharmaceutical Technology Co., Ltd.
Diffuse Large B-cell Lymphoma
 
 
NCT04668365: Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Recruiting
2
59
RoW
Rituximab, RiTUXimab Injection, Zanubrutinib, Zanubrutinib Pill, Cyclophosphamide, Cyclophosphamide Injection, Epirubicin, Epirubicin Injection, Vincristine, Vincristine Injection, Prednisone, Prednisone Pill
Henan Cancer Hospital
Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation
12/23
12/25
NCT04181489: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Recruiting
2
55
RoW
Sintilimab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
The First Affiliated Hospital with Nanjing Medical University
EBV-Positive DLBCL, Nos
12/23
12/23
NCT04481815: Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Recruiting
2
240
RoW
Rituximab, Lenalidomide, Methotrexate
Second Affiliated Hospital, School of Medicine, Zhejiang University
PCNSL
12/23
12/25
NCT04842487: R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study

Not yet recruiting
2
80
NA
R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)
Sun Yat-sen University
DLBCL
12/23
12/23
ECOG-ACRIN E1411, NCT01415752: Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Active, not recruiting
2
373
Canada, US
rituximab, bendamustine hydrochloride, bortezomib, lenalidomide
Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
Lymphoma, Neurotoxicity, Therapy-related Toxicity
12/24
09/31
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Recruiting
2
320
Canada
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Lymphoma
12/25
12/26
ChiCTR1900024918: Chidamide with Rituximab and lenalidomide for relapsed/refractory diffuse large B cell lymphoma, a multi-center, prospective, single arm, open label phase II trial

Not yet recruiting
2
40
 
treatment with chidamide, lenalidomide and rituximab
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Self-collected
Diffuse Large B Cell Lymphoma
 
 
NCT04129710: A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Recruiting
2
120
RoW
Ibrutinib, Lenalidomide, Methotrexate, Rituximab, Etoposide, PEGylated recombinant human granulocyte colony
Second Affiliated Hospital, School of Medicine, Zhejiang University, Ruijin Hospital, The First Affiliated Hospital of Nanchang University, Fujian Medical University Union Hospital, RenJi Hospital, Shanghai Tong Ren Hospital, Shandong Provincial Hospital, Cancer Hospital of Guangxi Medical University, Sir Run Run Shaw Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Zhejiang University
Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
12/23
12/25
NCT04400994: IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

Active, not recruiting
2
20
RoW
Rituximab, MabThera, IVIg, Privigen
The University of Hong Kong
Pemphigus
12/24
12/25
NCT04665765: Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
2
41
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
City of Hope Medical Center, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
03/24
03/24
ChiCTR2100046986: A prospective, single-arm, phase II, multi-center clinical study of zanubrutinib combined with rituximab and lenalidomide in the treatment of relapsed/refractory primary central nervous system lymphoma

Recruiting
2
22
 
Zebutinib, rituximab, and lenalidomide combined regimen treatment
The Affiliated Hospital of Nantong University; The Affiliated Hospital of Nantong University, self-funded
relapsed/refractory primary central nervous system lymphoma
 
 
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/27
NCT05073250: IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Recruiting
2
40
RoW
IBI376, PI3Kδ inhibitor, Rituximab, Anti-cluster of differentiation antigen 20 (CD20) monoclonal antibody
Chinese PLA General Hospital
Inert Non Hodgkin's Lymphoma
12/23
11/24
NCT05974085: XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Recruiting
2
10
RoW
Selinexor+RCHOP
Zhejiang Cancer Hospital
Double Hit Lymphoma, Triple Hit Lymphoma
12/23
03/24
NCT05049473: Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Recruiting
2
100
Europe
Rituximab, Methotrexate, Dexamethasone, Iphosphamid, Vincristine, Etoposide, Cytarabine, Cyclophosphamide, Doxorubicin, Vindesine, Hydrocortisone, Prednisone
PETHEMA Foundation, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL
01/24
01/24
NCT03863184: Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Hourglass Dec 2022 - Dec 2022 : Presentation of data from Phase 2 trial in combination with Lenalidomide and Rituximab for 1L MCL at ASH 2022
Active, not recruiting
2
35
US
Acalabrutinib, CALQUENCE, ACP-196, Lenalidomide, Revlimid, Rituximab, Rituxan
Weill Medical College of Cornell University, AstraZeneca, Celgene Corporation
Mantle Cell Lymphoma
09/24
09/27
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Recruiting
2
180
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
01/24
07/24
NCT04220008: Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Withdrawn
2
30
NA
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Clofarabine, Clofarex, Clolar, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Mycophenolate Mofetil, Cellcept, MMF, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
10/21
10/21
ORIENT, NCT05498259: Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Recruiting
2
46
RoW
Orelabrutinib, Rituximab, CHOP-like Regimen
The First Affiliated Hospital of Soochow University
Diffuse Large B-Cell Lymphoma
01/24
01/25
NCT05290337: ZR-CHOP in DLBCL With Specific Gene Abnormality

Recruiting
2
62
RoW
zanubrutinib
Fudan University
Diffuse Large B Cell Lymphoma
01/24
01/26
HNSZLYYNHL04, NCT04737889: Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

Recruiting
2
30
RoW
Rituximab, RiTUXimab Injection, Lenalidomide, Lenalidomide capsule, Methotrexate, Methotrexate Injectable Solution, Temozolomide, Temozolomide capsule
Henan Cancer Hospital
Primary Central Nervous System Lymphoma
01/24
01/26
NCT05186558: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Not yet recruiting
2
54
RoW
penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
The First Affiliated Hospital with Nanjing Medical University
Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
01/24
02/26
VEGA, NCT05564052 / 2022-000364-21: A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
36
Europe, US, RoW
Ibrutinib, JNJ-54179060, IMBRUVICA, PCI-32765, Lenalidomide, Rituximab, Bortezomib
Janssen Research & Development, LLC, Pharmacyclics LLC.
Lymphoma, Mantle-Cell
12/23
09/24
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
NCT03505762: Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

Active, not recruiting
2
80
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Wake Forest University Health Sciences, National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma
03/24
10/24
CWCLL-003, NCT05200312: A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

Recruiting
2
36
RoW
Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent)
The First Affiliated Hospital with Nanjing Medical University
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
02/24
02/25
NCI-2018-01186, NCT03147612: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Active, not recruiting
2
22
US
Blinatumomab, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Filgrastim, Filgrastim-aafi, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo, Ponatinib, AP-24534, AP24534, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Vincristine, Leurocristine, VCR, Vincrystine
M.D. Anderson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
02/25
02/25
NCT05398224: R-MTX-zanbrutinib in Secondary CNS Lymphoma

Recruiting
2
45
RoW
Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
Peking University
Secondary Central Nervous System Lymphoma
02/24
05/24
SAKK 35/14, NCT02451111: Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Terminated
2
190
Europe
Ibrutinib, Imbruvica®, Rituximab, MabThera®
Swiss Group for Clinical Cancer Research, Nordic Lymphoma Group
Follicular Lymphoma
12/22
07/23
ChiCTR2200056290: A single-arm, prospective, multicenter Phase II clinical study of rituximab combined with high-dose methotrexate and obitinib in the treatment of initially diagnosed elderly primary lymphoma of the central nervous system

Not yet recruiting
2
 
Affiliated Tumor Hospital of Xinjiang Medical University; Affiliated Tumor Hospital of Xinjiang Medical University, Nuocheng Jianhua Pharmaceutical Technology Co., Ltd
Primary central nervous system lymphoma
 
 
NCT03418038: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recruiting
2
80
US
Ascorbic Acid, 2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one, Asorbicap, C Vitamin, C-Long, Ce-Vi-Sol, Cecon, Cenolate, Cetane, Cevalin, L-Ascorbic Acid, VIT C, Vitamin C, Vitamin-C, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, JM8, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16-213, VP16, VP-16, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Placebo Administration, Questionnaire Administration, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Ikgdar, Mabtas, Decitabine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Core Biopsy, BIOPSY, CORE, CORE CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, ECHO, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Structural MRI, sMRI, Central Venous Cannula Insertion, Central venous catheter, Central Venous Catheter Placement, Portacath Placement, Port-a-cath Placement, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT SCAN, tomography
Mayo Clinic, National Cancer Institute (NCI)
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
12/25
03/26
Z+RCHOP/RDHAP, NCT06255704: A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients

Not yet recruiting
2
23
RoW
Zanubrutinib and RCHOP/RDHAP
Shanxi Province Cancer Hospital
Mantle Cell Lymphoma
01/26
12/27
NCT06301399: Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Not yet recruiting
2
20
RoW
Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy
Tianjin Medical University Cancer Institute and Hospital
Advanced Hepatocellular Carcinoma
12/25
12/26
GLORIFY, NCT06186648: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Recruiting
2
40
Europe
Glofitamab + Obinutuzumab
French Innovative Leukemia Organisation, Hoffmann-La Roche
Richter Syndrome
03/26
03/27
NCI-2023-08755, NCT06247540: Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Withdrawn
2
29
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Nivolumab, ABP 206, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Northwestern University, National Cancer Institute (NCI), Bristol-Myers Squibb, AbbVie
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
12/29
12/31
ChiCTR2200056256: Efficacy and safety of Lenalidomide, PD1 and BTK inhibitor / rituximab in the treatment of relapsed and refractory diffuse Large B-cell lymphoma

Recruiting
2
30
 
Lenalidomide，PD1 and BTK inhibitor / rituximab
Yancheng NO1.People's Hospital; Yancheng NO1.People's Hospital, Beijing InnoCare Pharma Co., Ltd
relapsed and refractory diffuse large B-cell lymphoma
 
 
NCT00848328: Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
30
US
Rituximab, Rituxan, MabThera, Lenalidomide, REVLIMID
University of California, Davis, Celgene
Lymphoma
04/24
12/24
PUMCH-NHL-013, NCT05390749: Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

Recruiting
2
50
RoW
Orelabrutinib, Pomalidomide, Rituximab, Methotrexate
Peking Union Medical College Hospital, Beijing Tiantan Hospital, Sanbo Brain Hospital Capital Medical University
Primary Central Nervous System Lymphoma
04/24
04/26
ChiCTR2200055554: A Observation Study of Thiotepa in Thetreatment of Primary Central Nervous System Lymphoma (PCNSL)

Recruiting
2
32
 
RM+TT ;R-CHOP + R + Thiotepa+ MTX regimen ;IR + Thiotepa (BTKi + rituximab + Thiotepa） ;carmustine + Thiotepa pretreatment
The Second Hospital of Lanzhou University; Lanzhou University Second Hospital, self-raised
Primary central nervous system lymphoma/Central?high?risk?of?diffuse?large?B-cell?lymphoma
 
 
NCT04840602: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Recruiting
2
92
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
03/28
03/28
NCT05392257: Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Recruiting
2
20
RoW
Rituximab + zanubrutinib + lenalidomide
Qingdao Central Hospital
Overall Survival
05/24
05/24
OSU-23307, NCT06390956: Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma

Not yet recruiting
2
23
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Pirtobrutinib, 5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide, BTK Inhibitor LOXO-305, Jaypirca, LOXO 305, LOXO-305, LOXO305, LY3527727, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
Narendranath Epperla, Eli Lilly and Company
Marginal Zone Lymphoma
12/25
12/25
NCT06362967: The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

Not yet recruiting
2
30
RoW
Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG, Intravenous Immunoglobin
Anhui Provincial Hospital
High Titers of Anti-HLA Antibody (MFI ≥5000)
12/25
06/26
EpLCART, NCT06414148: MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Not yet recruiting
2
40
RoW
Epcoritamab, Epcoritamab, lenalidomide and rituximab
Peter MacCallum Cancer Centre, Australia, AbbVie
Relapsed/Refractory Large B-cell Lymphoma
10/26
05/28
NCT04458610: Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
60
US
Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
05/26
05/26
NCT06263491: Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Recruiting
2
50
US
Rituximab, Rituxan, Pirtobrutinib
M.D. Anderson Cancer Center
Mantle Cell Lymphoma
03/25
03/27
19-C-0116, NCT04002947: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Recruiting
2
132
US
DA-EPOCH, Rituximab, CHOP, Acalabrutinib
National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
05/25
03/29
BV mini CHP, NCT02734771: A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting
2
24
US
Brentuximab vedotin, Adcetris, SGN-35, cAC10-vcMMAE, Rituximab, Rituxan, Mabthera, Cyclophosphamide, Cytoxan, Lyophilizedcytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin, Doxorubicin, Adriamycin, Doxil, Caelyx, Myocet, Prednisone, Deltasone, Orasone, Adasone, Deltacortisone, Prednisonum
Patrick Reagan, Seagen Inc.
Diffuse Large B-Cell Lymphoma
06/24
06/24
NCT03569995: [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

Recruiting
2
35
RoW
Rituximab, Truxima Inj, Methotrexate, Methotrexate Inj, Cytarabine Injection, Cytarabine
Won Seog Kim, Celltrion
Primary CNS Lymphoma
06/24
06/25
NCT03758989: A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

Recruiting
2
40
US
Rituximab Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
University of Rochester
DLBCL
06/24
06/26
NCT04047797: Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
24
US
Ixazomib, MLN-2238, MLN2238, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
06/24
06/24
COPA-R-CHOP, NCT04263584: Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

Active, not recruiting
2
62
Europe
Copanlisib, R-CHOP Chemotherapy
University Hospital Muenster, Bayer
Diffuse Large B Cell Lymphoma
04/25
04/25
NCT04416451: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

Active, not recruiting
2
6
US
Rituximab, Venetoclax
Memorial Sloan Kettering Cancer Center, AbbVie
Marginal Zone Lymphoma
06/24
06/24
NCT05290090: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Recruiting
2
31
RoW
Rituximab, Lenalidomide, Zanubrutinib and RCHOP, BGB-3111
Zhejiang Cancer Hospital
Diffuse Large B Cell Lymphoma
06/24
12/25
NCT06412068: A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Not yet recruiting
2
32
NA
Combined anti-PD-1 and R-CHOP
Sun Yat-sen University
Primary Mediastinal Large B Cell Lymphoma
06/26
06/26
NCT06412497: MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting
2
60
US
Rituximab, Rabbit ATG, Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, TBI, Cell Infusion, Post-Transplant G-CSF, Filgrastim, Tacrolimus, Mycophenolate Mofetil, MMF
Masonic Cancer Center, University of Minnesota
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
05/35
05/36
 

Download Options